Gufic Biosciences Limited AI Stock Analysis
Want to see IN:GUFICBIO full AI Analyst Report?
Gufic Biosciences Limited (GUFICBIO) AI Stock Analysis
Gufic Biosciences Limited
(NSE:GUFICBIO)
The score is held back primarily by weak and volatile cash flows (sharp FY2026 operating cash flow decline and negative free cash flow) and a high P/E valuation. Offsetting these risks, the technical setup is positive with the stock trading above major moving averages and moderate momentum readings.
Gufic Biosciences Limited (GUFICBIO) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 42.18B
- Dividend Yield
- 0.02%
- Average Volume (3M)
- 6,546
- Price to Earnings (P/E)
- 64.2
- Beta (1Y)
- 0.68
- Revenue Growth
- 16.70%
- EPS Growth
- 18.73%
- Country
- India
- Employees
- 1,491
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
Gufic Biosciences Limited Business Overview & Revenue Model
Company Description
Gufic Biosciences Limited is an Indian enterprise dedicated to the manufacturing and marketing of active pharmaceutical ingredients (APIs), generic medications, and related support services. The company's API and bulk drug offerings include antifunga...
Gufic Biosciences Limited Financial Statement Overview
Summary
Operating performance is decent (FY2026 gross margin ~36%, operating margin ~12.8%) and leverage is manageable (debt-to-equity ~0.61), but cash generation is a major weakness: operating cash flow fell sharply (~132M vs ~1.03B prior year) and free cash flow turned negative (FY2026 -180M). Margins and net income also declined in FY2026, reducing overall statement quality.
Income Statement
70PositiveBalance Sheet
68PositiveCash Flow
34Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.81B | 9.44B | 8.20B | 8.07B | 6.91B | 7.79B |
| Gross Profit | 4.52B | 3.40B | 2.97B | 4.07B | 3.51B | 3.56B |
| EBITDA | 1.66B | 1.54B | 1.38B | 1.48B | 1.37B | 1.50B |
| Net Income | 734.57M | 642.15M | 696.50M | 861.36M | 797.05M | 958.40M |
Balance Sheet | ||||||
| Total Assets | 0 | 13.42B | 11.69B | 10.93B | 8.61B | 5.21B |
| Cash, Cash Equivalents and Short-Term Investments | 621.86M | 762.17M | 290.22M | 11.37M | 286.02M | 116.08M |
| Total Debt | 0 | 4.05B | 3.36B | 3.33B | 3.34B | 643.87M |
| Total Liabilities | -6.65B | 6.77B | 5.68B | 5.60B | 5.13B | 2.52B |
| Stockholders Equity | 6.65B | 6.65B | 6.01B | 5.33B | 3.48B | 2.69B |
Cash Flow | ||||||
| Free Cash Flow | 434.82M | -180.11M | 270.96M | -1.20B | -2.14B | 187.86M |
| Operating Cash Flow | 591.15M | 131.71M | 1.03B | -74.57M | -265.87M | 1.06B |
| Investing Cash Flow | -152.90M | -319.73M | -717.09M | -1.02B | -1.91B | -945.89M |
| Financing Cash Flow | 150.53M | 652.67M | -163.26M | 823.81M | 2.34B | -62.44M |
Gufic Biosciences Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:GUFICBIO, the sentiment is Positive. The current price of 471.55 is above the 20-day moving average (MA) of 425.38, above the 50-day MA of 426.40, and above the 200-day MA of 358.63, indicating a bullish trend. The MACD of 13.98 indicates Negative momentum. The RSI at 64.83 is Neutral, neither overbought nor oversold. The STOCH value of 79.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:GUFICBIO.
Gufic Biosciences Limited Peers Comparison
Overall Rating
IN:BLISSGVS65Neutral
IN:GUFICBIO58Neutral
IN:MOREPENLAB57Neutral
IN:ORCHPHARMA54Neutral
IN:UNICHEMLAB51Neutral
IN:INDOCO48Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 65Neutral | INR 71.56B | 44.55 | ― | 0.22% | 24.87% | 46.37% | |
| 58Neutral | INR 47.29B | 64.21 | ― | 0.02% | 16.70% | 18.73% | |
| 57Neutral | INR 54.66B | 29.05 | ― | 0.20% | 30.20% | 91.17% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 54Neutral | INR 52.79B | 519.30 | ― | ― | 10.83% | -89.83% | |
| 51Neutral | INR 35.07B | 10.39 | ― | ― | 6.44% | 283.10% | |
| 48Neutral | INR 21.08B | 66.85 | ― | 0.09% | 10.75% | ― |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:GUFICBIO | Gufic Biosciences Limited | 471.55 | 156.83 | 49.83% | |
| IN:BLISSGVS | Bliss Gvs Pharma Limited | 673.00 | 510.22 | 313.45% | |
| IN:INDOCO | Indoco Remedies Limited | 228.30 | -32.27 | -12.39% | |
| IN:MOREPENLAB | Morepen Laboratories Limited | 99.75 | 53.60 | 116.13% | |
| IN:ORCHPHARMA | Orchid Pharma Limited | 881.50 | 23.55 | 2.74% | |
| IN:UNICHEMLAB | Unichem Laboratories Limited | 498.05 | 21.60 | 4.53% |
Gufic Biosciences Limited Corporate Events
Gufic Biosciences Receives USFDA Observations After Pre-Approval Inspection at Indore Plant
Gufic Biosciences Limited has disclosed that the U.S. Food and Drug Administration recently conducted a pre-approval inspection at its manufacturing facility in Indore, Madhya Pradesh, over the period from October 15 to October 23, 2026. The inspecti...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 30, 2026
